Join the Parkinsonism group to help and get support from people like you.
Parkinsonism News (Page 3)
FDA Approves Vyalev for Advanced Parkinson Disease
TUESDAY, Oct. 22, 2024 – The U.S. Food and Drug Administration has approved Vyalev (foscarbidopa and foslevodopa) for adults living with advanced Parkinson disease (PD). Vyalev is the first and only...
NFL Hall of Famer Brett Favre Has Parkinson's Disease
TUESDAY, Sept. 24, 2024 – Green Bay Packers legend and NFL Hall of Famer Brett Favre announced Tuesday that he has been diagnosed with Parkinson's disease. Favre, 54, made the announcement while...
Air Pollution Exposure Increases Risk for Parkinson Disease
FRIDAY, Sept. 20, 2024 – Higher exposure to air pollution increases the risk for Parkinson disease (PD), according to a study published online Sept. 16 in JAMA Network Open. Brittany Krzyzanowski,...
SGLT2i Use Linked to Lower Risk for Neurodegenerative Disease in T2DM
WEDNESDAY, Sept. 18, 2024 – For patients with type 2 diabetes, sodium-glucose cotransporter 2 inhibitor (SGLT2i) use is associated with reduced risks for incident dementia and Parkinson disease...
'Exercise Is Medicine' for People With Parkinson's
THURSDAY, Sept 19, 2024 – Exercise, whether moderate- or high-intensity, can help ease Parkinson's symptoms, including fatigue, new research shows. As study lead author Dr. Philip Millar explained,...
Some Diabetes Meds Could Lower Odds for Dementia, Parkinson's
THURSDAY, Sept. 19, 2024 – A specific class of diabetes drug appears to lower people’s risk for dementia and Parkinson’s disease, a new study shows. Sodium-glucose cotransporter-2 (SGLT2) inh...
FDA Approves Ongentys (opicapone) as an Add-On Treatment for Patients with Parkinson’s Disease Experiencing “Off” Episodes
SAN DIEGO – April 27, 2020 – Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that the U.S. Food and Drug Administration (FDA) has approved once-daily oral Ongentys (opicapone) 25 mg and 50...
FDA Approves Xadago (safinamide) as an Add-On Treatment for Patients with Parkinson’s Disease
March 21, 2017 – The U.S. Food and Drug Administration today approved Xadago (safinamide) tablets as an add-on treatment for patients with Parkinson’s disease who are currently taking l...
FDA Medwatch Alert: Benztropine Mesylate Injection (Nexus Pharmaceuticals): Recall - Visible Particulate Matter
ISSUE: Nexus Pharmaceuticals Inc. is recalling two lots of Benztropine Mesylate Injection, USP, 2 mg/2mL (1mg/mL) in 2 mL single dose vials due to the presence of visible particulate matter in the...